Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gain Therapeutics (GANX) Non-Current Assets (2020 - 2025)

Historic Non-Current Assets for Gain Therapeutics (GANX) over the last 6 years, with Q3 2025 value amounting to $454412.0.

  • Gain Therapeutics' Non-Current Assets fell 2721.54% to $454412.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $454412.0, marking a year-over-year decrease of 2721.54%. This contributed to the annual value of $521406.0 for FY2024, which is 3721.5% down from last year.
  • Per Gain Therapeutics' latest filing, its Non-Current Assets stood at $454412.0 for Q3 2025, which was down 2721.54% from $527277.0 recorded in Q2 2025.
  • Gain Therapeutics' 5-year Non-Current Assets high stood at $6.1 million for Q2 2022, and its period low was $454412.0 during Q3 2025.
  • In the last 5 years, Gain Therapeutics' Non-Current Assets had a median value of $855891.0 in 2023 and averaged $1.4 million.
  • In the last 5 years, Gain Therapeutics' Non-Current Assets surged by 49507.02% in 2022 and then crashed by 8427.55% in 2023.
  • Quarter analysis of 5 years shows Gain Therapeutics' Non-Current Assets stood at $1.3 million in 2021, then skyrocketed by 138.17% to $3.0 million in 2022, then tumbled by 72.39% to $830463.0 in 2023, then tumbled by 37.22% to $521406.0 in 2024, then decreased by 12.85% to $454412.0 in 2025.
  • Its last three reported values are $454412.0 in Q3 2025, $527277.0 for Q2 2025, and $472647.0 during Q1 2025.